260 related articles for article (PubMed ID: 17587834)
1. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women?
Hofmann MA; Coll SH; Küchler I; Kiecker F; Wurm R; Sterry W; Trefzer U
Dermatology; 2007; 215(1):10-6. PubMed ID: 17587834
[TBL] [Abstract][Full Text] [Related]
2. Survival and prognostic factors in patients with brain metastases from malignant melanoma.
Meier S; Baumert BG; Maier T; Wellis G; Burg G; Seifert B; Dummer R
Onkologie; 2004 Apr; 27(2):145-9. PubMed ID: 15138346
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
4. Determinants of outcome in melanoma patients with cerebral metastases.
Fife KM; Colman MH; Stevens GN; Firth IC; Moon D; Shannon KF; Harman R; Petersen-Schaefer K; Zacest AC; Besser M; Milton GW; McCarthy WH; Thompson JF
J Clin Oncol; 2004 Apr; 22(7):1293-300. PubMed ID: 15051777
[TBL] [Abstract][Full Text] [Related]
5. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
[TBL] [Abstract][Full Text] [Related]
6. Selection of patients with melanoma brain metastases for aggressive treatment.
Harrison BE; Johnson JL; Clough RW; Halperin EC
Am J Clin Oncol; 2003 Aug; 26(4):354-7. PubMed ID: 12902884
[TBL] [Abstract][Full Text] [Related]
7. [CNS metastases in malignant melanomas].
Willner J; Bohndorf W
Strahlenther Onkol; 1995 Mar; 171(3):165-73. PubMed ID: 7709333
[TBL] [Abstract][Full Text] [Related]
8. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity.
Radbill AE; Fiveash JF; Falkenberg ET; Guthrie BL; Young PE; Meleth S; Markert JM
Cancer; 2004 Aug; 101(4):825-33. PubMed ID: 15305416
[TBL] [Abstract][Full Text] [Related]
9. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
10. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.
Eigentler TK; Figl A; Krex D; Mohr P; Mauch C; Rass K; Bostroem A; Heese O; Koelbl O; Garbe C; Schadendorf D;
Cancer; 2011 Apr; 117(8):1697-703. PubMed ID: 21472716
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer metastatic to the brain: time trends in presentation and outcome.
Nieder C; Pawinski A; Balteskard L
Oncology; 2009; 76(5):369-74. PubMed ID: 19321946
[TBL] [Abstract][Full Text] [Related]
12. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients.
Broadbent AM; Hruby G; Tin MM; Jackson M; Firth I
Radiother Oncol; 2004 Jun; 71(3):259-65. PubMed ID: 15172140
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
15. Stage-IV melanoma and pulmonary metastases: factors predictive of survival.
Neuman HB; Patel A; Hanlon C; Wolchok JD; Houghton AN; Coit DG
Ann Surg Oncol; 2007 Oct; 14(10):2847-53. PubMed ID: 17680317
[TBL] [Abstract][Full Text] [Related]
16. Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma.
Hara W; Tran P; Li G; Su Z; Puataweepong P; Adler JR; Soltys SG; Chang SD; Gibbs IC
Neurosurgery; 2009 Feb; 64(2 Suppl):A26-32. PubMed ID: 19165071
[TBL] [Abstract][Full Text] [Related]
17. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB; Accortt NA; Shaw HM; Wiener M; Soong SJ; Hoekstra HJ; Thompson JF
Ann Surg Oncol; 2008 May; 15(5):1476-84. PubMed ID: 18196345
[TBL] [Abstract][Full Text] [Related]
18. Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors.
Lindholm C; Andersson R; Dufmats M; Hansson J; Ingvar C; Möller T; Sjödin H; Stierner U; Wagenius G;
Cancer; 2004 Nov; 101(9):2067-78. PubMed ID: 15372475
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival in melanoma patients with brain metastases.
Davies MA; Liu P; McIntyre S; Kim KB; Papadopoulos N; Hwu WJ; Hwu P; Bedikian A
Cancer; 2011 Apr; 117(8):1687-96. PubMed ID: 20960525
[TBL] [Abstract][Full Text] [Related]
20. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society.
Buettner PG; Leiter U; Eigentler TK; Garbe C
Cancer; 2005 Feb; 103(3):616-24. PubMed ID: 15630700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
